A Keck School of Medicine of USC study shows that cognitive tests can detect early Alzheimer’s disease in older adults who do not present symptoms yet. The study “Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis” was published in the journal Neuropsychology Review. It is…
News
Two surveys released today — the start of Alzheimer’s disease month — examine the emotional toll the condition places on caregivers, and their need for greater support. The results are both revealing and alarming. The online survey by the Alzheimer’s Association also delves into the serious lack of preparedness among the public,…
Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was approved by the U.S. Food and Drug Administration in April 2016 to treat similar problems with Parkinson’s patients. “We’re very pleased with…
In a recent Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention (CDC), researchers show that deaths due to Alzheimer’s disease increased almost 55% between 1999 and 2014. Also, more patients are perishing at home, which likely will increase the burden on family members or…
Researchers have discovered a common link between abnormal proteins that cause damage to brain cells in Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s (HD) disease patients. The discovery could help scientists understand the mechanism by which these neurodegenerative diseases spread, and possibly lead to a therapy…
A new DNA vaccine protects against accumulation of toxic proteins in Alzheimer’s disease, according to new research. One study, “Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer,” appeared in the Journal of Alzheimer’s…
Otsuka America Pharmaceutical and Avanir Pharmaceuticals are working with southern New Jersey educational administrators to create specialists who can help Alzheimer’s patients and their families navigate the care continuum. The goal is to start a one-year training program at Camden County College that leads to a specialist’s certification. Those receiving…
Epileptic-seizure-like activity in a brain region called the hippocampus may contribute to the development of Alzheimer’s, according to a case study involving two patients. And an anti-epileptic medicine may be able to slow the disease’s progression, Massachusetts General Hospital researchers said. An additional finding was that seizure-like activity may be difficult to…
Promising data from Sangamo Therapeutics‘ research programs, including Alzheimer’s disease, were recently announced. The results were presented during the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C. Sangamo’s work in Alzheimer’s revealed a significant reduction in the production of tau, a…
The Jackson Laboratory (JAX) is receiving a $2.7 million U.S. government grant for a five-year research project on the mechanisms that underlie healthy aging and Alzheimer’s disease. Dr. Catherine Kaczorowski, an assistant professor at the Bal Harbor, Maine-based research organization, will direct the work. The grant is coming from the National Institute on…
Recent Posts
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026